Leiterman
TL3 Regular · Split, HR
Laboratory background. Comfortable with chromatography, cautious about extrapolating from a single certificate.
Joined 29 January 2025 · last posted 12h · groups: analytical-chemists
139Posts here
5Topics
1Solutions
753Likes received
884Likes given
28Badges
235Days visited
2.4kPosts read
Stated areas
Recent activity
Full stream-
eGFR fluctuation and the creatinine denominator problem — the long version Replied, post #46 · Clinical › Bloodwork · 27 Jul 2026 · 10 likes A single value outside interval: usually uninformative on a single draw. What makes a result interesting: a trend across multiple draws, a magnitude well beyond the…
-
Spreadsheets: an appreciation — what changed since Replied, post #110 · Lounge › Off topic · 23 Jul 2026 · 7 likes Science communication: if you come across an interesting science paper or article about peptides or metabolism, sharing it and discussing the idea is on-topic.
-
Trust level 3 requirements: a clarification — does this still hold? Replied, post #87 · Meta › Announcements · 21 Jul 2026 · 0 likes When announcements are made: major policy changes, technical changes affecting site function, planned downtime, and changes to guidelines all get announced here.
-
Which categories are strict and which are relaxed, honestly Replied, post #35 · Start Here › Welcome · 21 Jul 2026 · 0 likes This follows post #32 rather than contradicting it. Introducing yourself is fine and requires no question. Post in this subcategory, describe the context that matters…
-
Why retatrutide discussion here is more cautious than elsewhere — one year on Replied, post #73 · Compounds › Retatrutide · 18 Jul 2026 · 31 likes Why this subcategory is more cautious than elsewhere: retatrutide is investigational, phase 3 is ongoing, and the heart-rate signal in phase 2 is not negligible.…
-
Journal club: what we got wrong in an earlier session Replied, post #95 · Evidence › Journal club · 18 Jul 2026 · 19 likes PIONEER 6 (N Engl J Med 2019): Cardiovascular safety trial for oral semaglutide, not efficacy. Non-inferiority for safety was met. The trial was not designed to…
-
Pooling trials with different estimands Replied, post #97 · Evidence › Meta-analyses · 14 Jul 2026 · 10 likes Two things before anyone answers the substance. First, the context in the first post is clear and specific. Second, the question is framed so that an answer can…
-
Coming back to: Solubility limits and what a cloudy solution is telling you Replied, post #39 · Pharmacology › Formulation chemistry · 11 Jul 2026 · 3 likes Two things before anyone answers the substance. First, the context in the first post is clear and specific. Second, the question is framed so that an answer can…
-
What consumer-accessible tests can and cannot determine — a second dataset Replied, post #73 · Analytics › Home & field testing · 11 Jul 2026 · 7 likes post #72 answers the question as asked. The question underneath it is different. Sample handling matters: if a sample is contaminated or degraded before testing, the…
-
Tracking a shortage from primary sources rather than rumour Replied, post #94 · Access › Shortages · 10 Jul 2026 · 0 likes Worth separating two things that post #90 runs together. Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did…
-
Why the absence of controlled human data on BPC-157 matters more than people admit Replied, post #56 · Compounds › Repair & healing peptides · 9 Jul 2026 · 25 likes Stability of BPC-157 in solution: what has been measured in published work covers specific formulations under specific conditions. Extrapolating to a reconstituted…
-
Documenting a supplier's response to a discrepancy Replied, post #30 · Sourcing › Vendor reports · 4 Jul 2026 · 18 likes Disputed records: when a result disagreed and was not explained, the record says disputed and stays that way. We do not remove inconvenient history; we document it.